ETON
Eton Pharmaceuticals, Inc. · Healthcare · Drug Manufacturers - Specialty & Generic
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 69 | +17 | 8.71M | $315.16M | +19 | −1 |
| Q1 2026 | 53 | 0 | 6.86M | $169.02M | +7 | −7 |
| Q4 2025 | 53 | +3 | 7.09M | $119.84M | +3 | — |
| Q3 2025 | 13 | +1 | 6.27M | $136.34M | +1 | — |
| Q2 2025 | 9 | -2 | 4.42M | $63.03M | +1 | −3 |
| Q1 2025 | 8 | +2 | 1.18M | $15.27M | +3 | −1 |
| Q4 2024 | 6 | +2 | 854.61K | $11.39M | +2 | — |
| Q3 2024 | 3 | -1 | 376.73K | $2.26M | +1 | −2 |
| Q2 2024 | 4 | — | 363.35K | $1.20M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Geode Capital Management ✦ (passive) | 240.33K | — | $790,884 | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 240.33K | — | $790,884 | 0.0% | n/c | 1 | SEC ↗ |
| 3 | Renaissance Technologies ✦ | 106.50K | — | $350,385 | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Two Sigma Investments ✦ | 16.48K | — | $54,236 | 0.0% | n/c | 1 | SEC ↗ |
| 5 | Citadel Advisors ✦ | 32 | — | $105 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 115 holders, 17.61M shares, $424.10M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 25.00K sh · $1.63M
Officer, Director · 47.31K sh · $2.85M
Officer, Director · 36.37K sh · $2.22M
Officer, Director · 7.34K sh · $456,085
Officer, Director · 8.98K sh · $562,472
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology